Commentary has the full details: doi.org/10.1162/IMAG...
Huge thanks to @mitulamehta.bsky.social for writing this fun piece with me and to Ruben and @coolscontrol.bsky.social for the thought provoking paper!
Feel free to reach out if you're interested in applying REACT to your own questions! :)
We've had this in the UK for ages. It makes a huge difference. Good luck holding on to it!
"For the first time we will gather detailed longitudinal assessments and high quality biosamples with voice, digital, genetics, proteomic and other biomarker data. This will give us a more complete picture of depression and its treatments than ever before." Professor Gerome Breen, King’s College London and NIHR Maudsley BRC
"We are excited to provide bespoke support for industry based on our expertise, the excellent networks and facilities in the UK and new tools to leverage our data resources, making the UK highly attractive for industry collaborations." Professor Mitul Mehta, King’s College London and NIHR Maudsley BRC
"The IoPPN has established itself at the forefront of mental health clinical trials. This programme builds on that expertise, bringing together the best of our methodological innovation and collaborative spirit to drive forward more effective, personalised treatments for those who need them most." Professor Richard Emsley, King’s College London and NIHR Maudsley BRC
📢 @kingscollegelondon.bsky.social will co-lead 2 of the 4 national workstreams in the £50m government–funded Mental Health Goals programme, helping to transform #MentalHealth data, #ClinicalTrials and #industry partnerships in the UK.
🔗Read more: www.kcl.ac.uk/news/kings-c...
Songs for these times thread: 🧵
“We are not free, but we are brave.” Leticia Van Sant, Home of the Brave.
youtu.be/vPaSQHzjA9s
Results from a large clinical trial, from IoPPN, @nihrmaudsleybrc.bsky.social, @unisouthampton.bsky.social, finds a trigeminal nerve stimulation device approved by the US FDA in 2019, is not an effective tool in reducing symptoms of #ADHD
Read the full story:
www.kcl.ac.uk/news/title-b...
BOLD signal changes can oppose oxygen metabolism across the human cortex, Nature Neuroscience
fMRI signals “up,” but neural metabolism might be going “down.”
In our @natneuro.nature.com paper, we demonstrate that about 40% of voxels with robust BOLD responses exhibit opposite oxygen metabolism, revealing two distinct hemodynamic modes.
rdcu.be/eUPO8
funds @erc.europa.eu
#neuroskyence 🧵:
A new spinout @cogstack.bsky.social is unlocking the power of healthcare data through #AI to transform clinical care. Read our story to discover more.
tinyurl.com/57ce8x43
@kingshealth.bsky.social @nihr.bsky.social @kingsioppn.bsky.social @kingscollegelondon.bsky.social
Jonny Smallwood @themindwanders.bsky.social was a beloved friend and mentor. He was taken from us too soon. His was a beautiful mind who understood the beauty of minds. As ever before, his kind voice guides me and his work will continue. We miss you Jonny. www.cbs.mpg.de/news/obituar...
BREAKING: “There is no doubting that the impact of Brexit is severe and long lasting” says Chancellor Rachel Reeves
It’s about time!
Just one more week to get submissions in for this!
Join us in Singapore to discuss the intersection of cog sci, comp. sci, psychiatry, and philosophy to understand Theory of Mind 🧠
DM me for informal qs 📜
@stefansarkadi.bsky.social @nitalon.bsky.social @reuth-mirsky.bsky.social
Post doc job alert 📢! Announcing a v exciting job on a Wellcome-funded project in my group at UCL, looking at auditory hallucinations... Advert here 👀: rb.gy/230w8l - deadline is end of Oct. Please apply! 1/5
The project is led by Oliver Howes at KCL, this job will be supervised by me, also @pgarner.bsky.social (who built the model) and @vaughanbell.bsky.social. Patient studies involve @mitulamehta.bsky.social, Kelly Diederen and others! 4/5
"US President Donald Trump has signed an executive order that will add a $100,000 (£74,000) annual fee for applicants to the H-1B visa programme for skilled foreign workers."
This is just another MASSIVE opportunity for Europe.
📖 Our letter of reply to 'pseudosocial' cognition is now out in @cp-trendscognsci.bsky.social
www.sciencedirect.com/science/arti...
Led by the talented @srazavi.bsky.social + written with @vaughanbell.bsky.social, Peter Dayan, @nicholaraihani.bsky.social, Michael Moutoussis
#NeuroPsychSky
Computational postdoc ad for KCL funded by the Wellcome Trust on the NEPTUNE project
🧠 We're hiring a computational postdoc!
3+ years with me & @mitulamehta.bsky.social on @wellcometrust.bsky.social funded social cognition/paranoia research at the IoPPN.
Lead & develop computational work, collaborate with experimentalists on psychosis/THC data.
DM for details! lnkd.in/eCMy9Jf5
Excellent write up by BAP Member Dr. Ed Chesney from the International Cannabinoid Research Society Annual Symposium whose attendance was supported by an award from the BAP (open to members studying for a higher degree through to 3 years post-PhD) - www.bap.org.uk/articles/int...
We are working with BipolarUK on a survey about medication (soon to be released). The same charity are asking for your support here. <10mins. Well worth a watch.
www.bbc.co.uk/programmes/m...
The full study is published today here: www.nature.com/articles/s41... :
Summary here:
www.kcl.ac.uk/news/ketamin...
and here: www.maudsleybrc.nihr.ac.uk/posts/2025/j...
Led by the excellent @lukejelenski.bsky.social 3/3
This mechanism could explain why the opiate antagonist reduces ketamine’s glutamate surge. The subsequent reduction in the antidepressant response suggests this glutamate mechanism is necessary. 2/3
New research in those with depression shows the opioid system is involved in ketamine's antidepressant response. The doses of ketamine used to treat depression are unlikely to interact directly with opioid receptors, but are co-expressed with NMDA receptors on GABAergic interneurons. 1/3
Dr Luke Jelen, lead author of the study and a Clinical Lecturer in Psychiatry at IoPPN King’s College London, said: “Ketamine often makes the news for negative reasons. However, at a low dose, ketamine shows enormous potential to offer relief from the symptoms of depression.” “Understanding whether the opioid system is involved ketamine’s antidepressant effects is a really important question, given how much we still don't know about how ketamine works. “Our study shows that the opioid system is involved and offers insight into how it contributes to ketamine’s effects.”
Research which is investigating why ketamine could be a good treatment for some people with depression, has discovered that the drug’s antidepressant effects involve the brain’s opioid system.
The study was supported by @nihr.bsky.social and the MRC.
www.maudsleybrc.nihr.ac.uk/posts/2025/j...
*without CB2 ligands!
No, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no, no... Just, NO!
Now @mattwall.bsky.social shares his insights into what neuroimaging has taught us about psychedelic mechanisms. #BAP2025
How can you get at the cannabis CB2 receptor function with CB2 ligands. Dr. Ekaterina Shatalina has used the connectivity approach REACT to address this #BAP2025
Challenges in drug development is a theme and this year's #BAP2025 and Prof. Neil Harrison talks about de-risking in development of a novel compound.
Final day of #BAP2025 kicks off with Dr. Diana Cash taking us through translational pharmacological imaging. Multimodal, multi-drug and multi-studies!
Barod ketamine conference begins in Swansea #barod25
The unspoken shall be spoken! Looking forward to it. @kingsioppn.bsky.social
